How we used a hybrid qual-quant methodology to assess the market opportunity for a new rare disease treatment
Our client is a recently established independent biopharmaceutical company specialising in small molecule development. They were developing a new oral compound for the treatment of a rare genetic disease for which the standard treatment is administered intravenously, however a large proportion of patients receive monitoring only or remain undiagnosed. Their objective was to successfully launch their product in order to provide clinically meaningful benefits to patients and contribute to the overall growth of their business.
How we helped track and evaluate conference performance over time across multiple international events
Our client planned to have a significant presence at key global conferences over the course of a year. Find out how we effectively monitored perceptions of their brand across different regions over time.
Our client was developing a portfolio for the treatment of a chronic neurodegenerative disease and planned to have a significant presence at key neuroscience conferences over the coming year. With conferences being a considerable investment, they wanted to understand how various aspects of their presence and presentations n(vs competitors) at each event impacted their target.
How we used behavioural economic theory to reveal fresh insights into patient compliance
Our client currently has a product for a chronic rare disease which has seen an initial successful uptake. HCPs appear to support the product and are actively prescribing it to suitable patients.
However, sales data suggests that repeat prescriptions drastically reduce after the first 3-6 months. Although the product has a known SE profile, our client believes that this can be well managed and controlled.
How we assessed the access potential of a new product in order to develop a successful launch strategy
Our client had two regimens in clinical development for the front-line treatment of an oncology condition using a breakthrough product; and planned to release outcomes data at key industry events throughout the year.
To ensure a fast and successful launch they wanted to develop key strategies to maximise acceptance and reimbursement of their product amongst HCPs and Payers.
How we facilitated mock negotiations with payers to improve the pricing strategy for a new biologic in Latin America
Our client wanted to understand how they should manage payer objections within the value proposition, clinical evidence and economic value of the product.
At offered prices, it would be cost-effective and have comparable / lower net budget impact than analogues. However, payers in Latin America were still expected to add further barriers or reject the reimbursement request. As a result our client wanted to understand how they should manage payer objections within the value proposition, clinical evidence and economic value of the product.